Companies
/Healthcare
Morphosys AG
$18.96
▲ $0.00 (+0.00%) today
Markets closed · 9:01pm ET
MOR at a Glance
Valuation
- Market cap
- $2.9B
Profitability
- Revenue (TTM)
- $241.5M
- Profit margin
- -190.6%
- EPS (TTM)
- $-1.50
Price
- Street target
- $15.58
Headquartered in Semmelweisstrasse 7, Planegg Fiscal year ends December NASDAQ: MOR morphosys.com
About MOR
MorphoSys AG is a biopharmaceutical company based in Germany, focused on developing therapeutic antibodies for cancer and autoimmune diseases. It has brought to market Tafasitamab for B cell malignancies and is working on treatments for conditions like myelofibrosis, autoimmune diseases, Alzheimer’s, and rheumatoid arthritis. The company collaborates globally, including partnerships for developing and commercializing its products in various regions. Founded in 1992, MorphoSys stands out for its commitment to addressing unmet medical needs through innovative therapies.
Frequently Asked Questions
What does MOR do?
MorphoSys AG is a biopharmaceutical company based in Germany, focused on developing therapeutic antibodies for cancer and autoimmune diseases.
What is the MOR stock price target?
The Wall Street consensus 12-month price target for MOR is $15.58.